MMP2 and neoplasm: Future refinements involve stimuli-cleavable linkers [e.g., matrix metalloproteinase-2 (MMP2)-sensitive peptides] that unmask ligands in the tumor microenvironment, mitigating peripheral binding and extending half-life by 2–3-fold, as validated in orthotopic pancreatic cancer models with 90% tumor growth inhibition versus 50% for static ligands [23].